Small cap wrap: Tiziana Life Sciences, Thistle Resources, Alvopetro, BioHarvest...
…
1,655$
12,59%
Echtzeit-Aktienkurs Tiziana Life Sciences Ltd
Bid:
Ask:
Nachrichten zur Tiziana Life Sciences Ltd Aktie
Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration
Tiziana Life Sciences Ltd (NASDAQ:TLSA) was awarded a Buy rating with a $7 price target by BTIG, which pointed to the…
Market movers: Strategy, Bitmine, Tiziana Life Sciences...
…
Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it will present a poster on its Phase 2a BANYAN clinical trial of…
Small cap wrap: Medicus Pharma, Tiziana Life Sciences, Namibia Critical Metals...
…
Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete…
Small cap wrap: Power Metallic Mines, Tiziana Life Sciences, Fox Tungsten, American Resources…
…
Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said the last patient in its Phase 2a clinical trial has received a first dose…
Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple...…
Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has completed patient enrollment in its Phase 2a clinical trial evaluating intranasal…
Tiziana Life Sciences price target boosted on foralumab update
Tiziana Life Sciences Ltd (NASDAQ:TLSA) saw Lucid Capital Markets raise its 12-month price target on the company to $9 from…
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides...
…
Tiziana Life Sciences reports encouraging one-year data for intranasal foralumab in progressive MS
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that updated data from its Expanded Access Program showed intranasal foralumab continued…
Small cap wrap: VivoPower, BioHarvest Sciences, Phunware, Tiziana Life Sciences…
…
Tiziana Life Sciences reports brain inflammation reductions in Multiple System Atrophy trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported PET imaging results from two patients in a Phase 2 Multiple System Atrophy trial…
Small cap wrap: 1911 Gold, Sona Nanotech, Tiziana Life Sciences, Gunnison Copper…
…
Market movers: Tesla, Wells Fargo, Lucid Group, Tiziana Life Sciences, Trillion Energy…
…
Tiziana Life Sciences to present Phase 2a MSA study at World Parkinson Congress
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday a late-breaking poster on its Phase 2a study of intranasal foralumab in…
Market movers: Nike, RH, Tiziana Life Sciences, Eli Lilly…
…
Tiziana Life Sciences reports positive preclinical findings for intranasal anti-CD3 therapy in brain aging
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has unveiled new preclinical data suggesting that its investigational therapy, intranasal foralumab, may offer a...…
Market movers: Circle Internet Group, Tiziana Life Sciences, Cava, Lowe’s…
…
Small cap wrap: American Resources, Tiziana Life Sciences, Digi Power X, Midnight Sun Mining...
…
Tiziana Life Sciences publishes positive study on intranasal MS therapy
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday that a peer-reviewed study of its experimental intranasal therapy for secondary progressive…
Small cap wrap: Nextech3D.ai, Aftermath Silver, Tiziana Life Sciences, AtaiBeckley…
…
Tiziana Life Sciences announces closing of oversubscribed $8.8M offering
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has closed an $8.8 million equity financing backed by its senior leadership…
Tiziana Life Sciences unveils registered direct offering of up to $17.6M
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the pricing of a registered direct offering expected to raise up to approximately…
Small cap wrap: Tiziana Life Sciences, 374Water, First Phosphate...
…
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has submitted its seventh annual Development Safety Update Report (DSUR) to the…
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi talked with Proactive about a series of important developments for the company, including…
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial
…
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics…
…
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Wednesday it has dosed the first patient in a Phase 2 clinical trial…
Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer’s trial next week
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has begun enrolling participants in its Phase 2 randomized, placebo-controlled clinical trial...…
Small cap wrap: Tiziana Life Sciences, Gunnison Copper, Blockmate Ventures, Century Lithium…
…
Tiziana Life Sciences plans spinout of IL-6 antibody program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Tuesday it plans to spin out its anti-IL-6 receptor antibody program, TZLS-501, into…
Small cap wrap: Tiziana Life Sciences, Pinnacle Silver & Gold, Rainbow Rare Earths...
…
Tiziana Life Sciences’ Phase 2 foralumab trial joins Healey ALS MyMatch Program
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral...…
Tiziana Life Sciences: Foralumabs Intranasal Push Is A Good Moonshot
…
Tiziana Life Sciences to showcase drug candidate at Saudi innovation forum
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh,…
Market movers: Gunnison Copper, Tiziana Life Sciences, Seeing Machines...
…
Tiziana Life Sciences stock higher on inflammatory therapy plans
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance...…
Small cap wrap: Arizona Gold & Silver, Fineqia, Tiziana Life Sciences...
…
Tiziana Life Sciences reports encouraging results from nasal Alzheimer’s treatment
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said that its experimental nasal treatment for Alzheimer’s disease showed promising results in a patient,…
Small cap wrap: Tiziana Life Sciences, Challenger Energy, Arrow Exploration...
…
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center…
Tiziana Life Sciences’ foralumab reduced neuroinflammation in Alzheimer’s patient, study shows
Tiziana Life Sciences Ltd (NASDAQ:TLSA)’ investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a...…
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer’s patient treated with nasal foralumab
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer’s disease showed a marked reduction in…
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2…
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2…